United Therapeutics Reports Q2 2026 Financial Results with Revenue Decline and Increased Net Income

United Therapeutics Corporation reported its financial results for the second quarter of 2026, revealing total revenues of $783.3 million, a decrease of 2% from $798.6 million in the same period of 2025. For the first half of 2026, revenues also fell to $1.564 billion from $1.593 billion year-over-year. The company’s net income for the second quarter was $333 million, up from $309.5 million in the prior year, resulting in a diluted earnings per share of $7.27 compared to $6.41 in the same quarter of 2025. The increase in net income was attributed to a reduction in income tax expense and a slight increase in operating income, despite a rise in operating expenses.

The company experienced notable changes in its product sales, particularly with its treprostinil-based therapies. Sales of Tyvaso DPI increased by 4% to $326.6 million for the second quarter, while Nebulized Tyvaso sales decreased by 18% to $126 million, reflecting a decline in U.S. quantities sold. Remodulin sales also fell by 6% to $126.3 million. The overall decrease in revenues was attributed to increased competition from generic products and other therapies, which negatively impacted sales of Nebulized Tyvaso and Remodulin.

In terms of strategic developments, United Therapeutics completed the acquisition of Thymmune Therapeutics, Inc. for approximately $140 million, with potential earnout considerations of up to $160 million based on clinical milestones. This acquisition aligns with the company's focus on developing regenerative therapies. Additionally, the company has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indications for Nebulized Tyvaso to include idiopathic pulmonary fibrosis (IPF), following successful clinical trials.

Operationally, United Therapeutics reported a cash and cash equivalents balance of $1.803 billion as of June 30, 2026, an increase from $1.557 billion at the end of 2025. The company also engaged in significant share repurchase activities, repurchasing 2.76 million shares under its $2 billion share repurchase program, which is set to expire in March 2027. The company’s employee headcount has increased, reflecting its ongoing investments in research and development, which totaled $146.3 million for the second quarter, up from $134 million in the same period last year.

Looking ahead, United Therapeutics anticipates continued revenue growth driven by the expansion of its product portfolio, including the anticipated launch of ralinepag extended-release tablets and the approval of Nebulized Tyvaso for IPF. The company remains focused on addressing the competitive landscape and regulatory challenges while leveraging its strong cash position to support ongoing operations and strategic initiatives.